Abstract:Background: The androgen receptor (AR) plays important roles in the development of male phenotype and in different human diseases including prostate cancers. The AR can act either as a promoter or a tumor suppressor depending on cell types. The AR proliferative response program has been well studied, but its prohibitive response program has not yet been thoroughly studied.Methodology/Principal Findings: Previous studies found that PC3 cells expressing the wild-type AR inhibit growth and suppress invasion. We applied expression profiling to identify the response program of PC3 cells expressing the AR (PC3-AR) under different growth conditions (i.e. with or without androgens and at different concentration of androgens) and then applied the newly developed ChIP-seq technology to identify the AR binding regions in the PC3 cancer genome. A surprising finding was that the comparison of MOCK-transfected PC3 cells with AR-transfected cells identified 3,452 differentially expressed genes (two fold cutoff) even without the addition of androgens (i.e. in ethanol control), suggesting that a ligand independent activation or extremely low-level androgen activation of the AR. ChIP-Seq analysis revealed 6,629 AR binding regions in the cancer genome of PC3 cells with an FDR (false discovery rate) cut off of 0.05. About 22.4% (638 of 2,849) can be mapped to within 2 kb of the transcription start site (TSS). Three novel AR binding motifs were identified in the AR binding regions of PC3-AR cells, and two of them share a core consensus sequence CGAGCTCTTC, which together mapped to 27.3% of AR binding regions (1,808/ 6,629). In contrast, only about 2.9% (190/ 6,629) of AR binding sites contains the canonical AR matrix M00481, M00447 and M00962 (from the Transfac database), which is derived mostly from AR proliferative responsive genes in androgen dependent cells. In addition, we identified four top ranking co-occupancy transcription factors in the AR binding regions, which include TEF1 (Transcriptional enhancer factor), GATA (GATA transcription factors), OCT (octamer transcription factors) and PU1 (PU.1 transcription factor).Conclusions/Significance: Our data provide a valuable data set in understanding the molecular basis for growth inhibition response program of the AR in prostate cancer cells, which can be exploited for developing novel prostate cancer therapeutic strategies.

The Applications of Chromatin Immunoprecipitation in the Study on the Downstream Target Genes of Androgen Receptor in Prostate Cancer Cells

Development and Application of Prostate Cancer Gene 3 in Prostate Cancer

Non-coding RNAs: emerging roles in the characterization of immune microenvironment and immunotherapy of prostate cancer

Characterization of the Small RNA Transcriptomes of Androgen Dependent and Independent Prostate Cancer Cell Line by Deep Sequencing

Integrated Expression Profiling And Chip-Seq Analyses Of The Growth Inhibition Response Program Of The Androgen Receptor

The research progress of precision medicine for prostate cancer based on genomics

Chromatin Profiles Classify Castration-Resistant Prostate Cancers Suggesting Therapeutic Targets.

Identification of Novel AR-Targeted MicroRNAs Mediating Androgen Signalling Through Critical Pathways to Regulate Cell Viability in Prostate Cancer

Modulating Treg cell activity in prostate cancer via chitosan nanoparticles loaded with si-BATF/PRDM1

Androgen Receptor-Related Non-coding RNAs in Prostate Cancer

Emerging Proteins in CRPC: Functional Roles and Clinical Implications

Advances in the Current Understanding of the Mechanisms Governing the Acquisition of Castration-Resistant Prostate Cancer

Research Progress for the Clinical Application of Circulating Tumor Cells in Prostate Cancer Diagnosis and Treatment

Molecular Mechanisms of Noncoding RNA in the Occurrence of Castration-Resistant Prostate Cancer

Abstract B026: Chromatin Profiles Classify Castration-Resistant Prostate Cancers Suggesting Therapeutic Targets

Chem-Seq Permits Identification Of Genomic Targets Of Drugs Against Androgen Receptor Regulation Selected By Functional Phenotypic Screens

Insights into immune microenvironment and therapeutic targeting in androgen-associated prostate cancer subtypes

Molecular landscape for risk prediction and personalized therapeutics of castration-resistant prostate cancer: at a glance

Systematic Multi-Omics Investigation of Androgen Receptor Driven Gene Expression and Epigenetics changes in Prostate Cancer

Recent Advances in DNA Repair Pathway and Its Application in Personalized Care of Metastatic Castration-Resistant Prostate Cancer (mCRPC)

eRNAs and Superenhancer lncRNAs Are Functional in Human Prostate Cancer